An Open-Label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-Line Systemic Atezolizumab Combined with Bevacizumab in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined